Eli Lilly’s Mounjaro is a game-changer, proving to be substantially more efficient than Novo Nordisk’s Ozempic in producing weight-loss in clients with obese or weight problems, a brand-new real-world research study has found.
The analysis of 18,000 clients revealed that those taking Mounjaro were 3 times more likely than those taking Ozempic to achieve 15% weight-loss, according to the research study by Truveta Research, which examines de-identified client information from a cumulative of health systems. After one year of treatment, the clients taking Mounjaro lost a typical 15.2% of their …
Master your cash. Register for MarketWatch.
Get this short article and all of MarketWatch. Gain access from any gadget. Anywhere. Anytime.
Currently a customer?
Visit